A lawsuit alleges Anthony Mack breached the "restrictive covenants agreement" he entered into with Sorrento Therapeutics when he sold all of his shares in Scilex, a pain medicine developer, for about $12 million in 2016.
A lawsuit alleges Anthony Mack breached the "restrictive covenants agreement" he entered into with Sorrento Therapeutics when he sold all of his shares in Scilex, a pain medicine developer, for about $12 million in 2016.
